A phase II study of bortezomib added to standard daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine (Int-DAC) for consolidation in patients with previously untreated acute myeloid leukemia (AML) age 60-75 years: CALGB study 10502.
Year: 2012
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Eyal C. Attar, Jeffrey L. Johnson, Philip C. Amrein, Gerard Lozanski, Martha Wadleigh, Daniel J. DeAngelo, Jonathan E. Kolitz, Bayard L. Powell, Peter Michael Voorhees, Eunice S. Wang, William G. Blum, Guido Marcucci, Clara D. Bloomfield, Barry K Moser, Richard M. Stone, Richard A. Larson, CALGB
Institutions: Massachusetts General Hospital, Duke Cancer Institute, The Ohio State University, Harvard University, Dana-Farber Cancer Institute, Northwell Health, Hofstra University, Wake Forest University, University of North Carolina at Chapel Hill, Roswell Park Comprehensive Cancer Center, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Duke Medical Center, University of Chicago
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W1926806443